This Just In: More Upgrades and Downgrades
At The Motley Fool, we poke plenty of fun at Wall Street analysts and their endless cycle of upgrades, downgrades, and "initiating coverage at neutral." While the pinstripe-and-wingtip crowd is entitled to its opinions, we've got some pretty sharp stock pickers down here on Main Street, too. (And we're not always impressed with how Wall Street does its job.)
Given this, perhaps we shouldn't be giving virtual ink to "news" of analyst upgrades and downgrades. And we wouldn't -- if that were all we were doing. Fortunately, in "This Just In," we don't simply tell you what the analysts said. We also show you whether they know what they're talking about.
Today, we're going to take a look at three high-profile ratings moves on Wall Street: New buy ratings have just been issued for biotechs Ariad Pharmaceuticals (NAS: ARIA) and Human Genome Sciences (NAS: HGSI) . On the other hand, ArcelorMittal (NYS: MT) just lost its buy rating.
ArcelorMittal's new rating: neutral
Let's get the bad news out of the way first. Yesterday, we looked at how a previously spooked Wall Street may be moving back into steel stocks, with Wells Fargo leading the way with an upgrade for AK Steel. Today, though, another analyst is stomping on the brakes, and warning, "Not so fast." This morning, the analyst in question, HSBC Securities, downgraded shares of the world's biggest steelmaker, ArcelorMittal.
According to HSBC, there's a limit to how much profit Arcelor can earn before attracting cut-price competition from Chinese steelmakers. Analysts looking for $0.12 per share out of Arcelor in its next quarterly report, and an even more robust $0.50 profit in Q1 of 2012, are going to get their hopes dashed. Accordingly, HSBC says you should sit on the sidelines till the damage has been done.
I agree. Arcelor's profit margins are already pretty high. At 7.7% operating margin, the company outshines U.S. Steel by a factor of... 7.7. So there's little room for improvement on the margins front. Meanwhile, Arcelor continues to struggle under the weight of a $25 billion net-debt load -- and yes, it's still free-cash-flow negative.
Ariad Pharma's new rating: buy
Turning now to the biotech industry: Ariad Pharma is no stranger to cash-burn either. But according to a new report out of Maxim Group, the cancer researcher's ponatinib and AP26113 compounds are "superior" to other drugs on the market, and make this company an attractive acquisition target. Over at The Motley Fool Blog Network, prolific commentator Robert Fisher also likes Ariad's ridaforolimus treatment for "metastatic soft-tissue or bone sarcomas." Ariad is partnering with Merck (NYS: MRK) on that one, which means it's got to share the profits, which limits the upside for Ariad stock.
Will Merck (or someone else?) buy Ariad's cow instead of just milking the company for cheap access to new drugs? It's possible. The company had more than $73 million in net cash at last report, which means that for the time being, Ariad can negotiate a sale from a position of strength -- but this window is closing fast. With a cash-burn rate exceeding $44 million annually, Ariad has less than two years to either raise new capital through debt or dilutive stock issuances, or seal a deal with an acquirer.
Human Genome's new rating: buy
Last but not least, Maxim also likes the prospects for Human Genome. Yesterday, my fellow Fool Sean Williams highlighted the possibility that GlaxoSmithKline (NYS: GSK) might buy the company for its Benlysta lupus drug. (You guessed it -- Glaxo is Human Genome's marketing partner on Benlysta.)
Human G's in a trickier position than Ariad, however. While flush with cash on the surface ($540 million cash and equivalents), the company has $525 million in debt, which basically cancels that out. Making matters worse, it's burning cash much faster than Ariad is, with annual cash burn approaching $410 million. If a buyout's going to happen here, it had better happen fast, or else Human Genome will be forced to avail itself of the dilution solution.
Foolish final thought
Personally, I would not buy any of these stocks. As I've said many times already, I'm no huge fan of negative free cash flow. ArcelorMittal seems unattractive to me on this score, especially when there are better options available. And as for the biotechs, Ariad and Human Genome, is there potential for a cash payday when a buyout materializes? Sure there is -- but I don't like to rely on the kindness of strangers to bail me out of bad investment decisions. I might not be brave enough to bet against these biotechs (because sometimes, strangers do strange things), but I wouldn't risk my money on 'em, either.
At the time this article was published The Motley Fool owns shares of ArcelorMittal, andMotley Fool newsletter serviceshave recommended buying shares of GlaxoSmithKline, but Fool contributorRich Smithdoes not own shares of, nor is he short, any company mentioned above. (He does, however, have public recommendations available on 56 separate companies. Check them out on Motley Fool CAPS page, where he goes by the handleTMFDitty-- and is currently ranked No. 349 out of more than 180,000 CAPS members.)The Motley Fool has adisclosure policy.We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.